On Air Now

Now Playing

Our Playlist »

Listen

Listen Live Now » 93.7 FM Fargo-Moorhead

Weather

Current Conditions(Fargo,ND 58103)

More Weather »
76° Feels Like: 76°
Wind: S 25 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Showers 57°

Tomorrow

Partly Cloudy 77°

Wed Night

Clear 57°

Alerts

Bind Therapeutics ends cancer drug partnership with Amgen

(Reuters) - Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

Bind's shares fell 15 percent to $10.95 in extended trading on Wednesday. Angen's shares were little changed from their close of $121.03.

"Despite achieving the objective of high tumor concentrations, the results were not sufficiently compelling to proceed forward and both collaborators have agreed that the program will not be continued," Bind's Chief Executive Scott Minick said in a statement.

The company had entered into a twelve-month collaboration agreement with Amgen in January 2013 to develop cancer treatments using Bind's nanotechnology platform and an Amgen compound.

(Reporting By Anjalirao Koppala in Bangalore; Editing by Savio D'Souza)

Comments